Safety, Tolerability, and Effect of Nusinersen in Non-ambulatory Adults With Spinal Muscular Atrophy
Objective: Investigation of the safety, tolerability, and treatment effect of nusinersen treatment in non-ambulatory adults with spinal muscular atrophy (SMA).Methods: Non-ambulatory individuals, aged 18 years or older with genetically confirmed 5q SMA were enrolled. In participants with spinal fusi...
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-04-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2021.650532/full |
id |
doaj-4b859026bc0841c3adf44b99c2a49418 |
---|---|
record_format |
Article |
spelling |
doaj-4b859026bc0841c3adf44b99c2a494182021-04-16T05:36:36ZengFrontiers Media S.A.Frontiers in Neurology1664-22952021-04-011210.3389/fneur.2021.650532650532Safety, Tolerability, and Effect of Nusinersen in Non-ambulatory Adults With Spinal Muscular AtrophyBakri Elsheikh0Steven Severyn1Songzhu Zhao2David Kline3Matthew Linsenmayer4Kristina Kelly5Marco Tellez6Amy Bartlett7Sarah Heintzman8Jerry Reynolds9Gary Sterling10Tristan Weaver11Kiran Rajneesh12Stephen J. Kolb13W. David Arnold14Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, United StatesDepartment of Anesthesiology, The Ohio State University Wexner Medical Center, Columbus, OH, United StatesDepartment of Biomedical Informatics and Center for Biostatistics, The Ohio State University, Columbus, OH, United StatesDepartment of Biomedical Informatics and Center for Biostatistics, The Ohio State University, Columbus, OH, United StatesAssistive Technology Department, The Ohio State University Wexner Medical Center, Columbus, OH, United StatesDepartment of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, United StatesDepartment of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, United StatesDepartment of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, United StatesDepartment of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, United StatesDepartment of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, United StatesDepartment of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, United StatesDepartment of Anesthesiology, The Ohio State University Wexner Medical Center, Columbus, OH, United StatesDepartment of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, United StatesDepartment of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, United StatesDepartment of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, United StatesObjective: Investigation of the safety, tolerability, and treatment effect of nusinersen treatment in non-ambulatory adults with spinal muscular atrophy (SMA).Methods: Non-ambulatory individuals, aged 18 years or older with genetically confirmed 5q SMA were enrolled. In participants with spinal fusion, fluoroscopy guided cervical C1–C2 lateral approach was used. Outcomes at 2, 6, 10, and 14 months post-treatment were compared with baseline assessment. Forced vital capacity (FVC) was the primary outcome, and RULM, HFMSE, the modified SMA-FRS, and ulnar nerve electrophysiology [compound muscle action potential (CMAP), single motor unit size, and motor unit number] were secondary. Adverse and serious adverse events and clinically significant vital sign or lab abnormalities were recorded.Results: Results from 12 women and 7 men (mean age: 39.7 ± 13.9, range: 21–64 years) were analyzed. No clinically significant changes of vital signs or laboratory parameters were observed. Five participants were hospitalized for pneumonia. Other adverse events included headache, back pain, cervical injection site pain, and upper respiratory and urinary tract infections. High baseline protein/creatinine ratio without significant change on treatment noted in 4 participants. FVC was feasible in all participants. HFMSE and RULM were not feasible in the majority of participants. FVC and functional outcomes were stable without improvement. CMAP and single motor unit potential sizes showed enlargement while motor unit numbers were stable.Conclusions: Nusinersen, including C1/C2 delivery, was safe overall and well-tolerated. Several outcome measures were limited by floor effect. Overall, treatment resulted in stability of motor outcomes, but motor unit and CMAP size were increased.https://www.frontiersin.org/articles/10.3389/fneur.2021.650532/fulladultsSMAnon-ambulatorynusinersensafetyMUNE |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Bakri Elsheikh Steven Severyn Songzhu Zhao David Kline Matthew Linsenmayer Kristina Kelly Marco Tellez Amy Bartlett Sarah Heintzman Jerry Reynolds Gary Sterling Tristan Weaver Kiran Rajneesh Stephen J. Kolb W. David Arnold |
spellingShingle |
Bakri Elsheikh Steven Severyn Songzhu Zhao David Kline Matthew Linsenmayer Kristina Kelly Marco Tellez Amy Bartlett Sarah Heintzman Jerry Reynolds Gary Sterling Tristan Weaver Kiran Rajneesh Stephen J. Kolb W. David Arnold Safety, Tolerability, and Effect of Nusinersen in Non-ambulatory Adults With Spinal Muscular Atrophy Frontiers in Neurology adults SMA non-ambulatory nusinersen safety MUNE |
author_facet |
Bakri Elsheikh Steven Severyn Songzhu Zhao David Kline Matthew Linsenmayer Kristina Kelly Marco Tellez Amy Bartlett Sarah Heintzman Jerry Reynolds Gary Sterling Tristan Weaver Kiran Rajneesh Stephen J. Kolb W. David Arnold |
author_sort |
Bakri Elsheikh |
title |
Safety, Tolerability, and Effect of Nusinersen in Non-ambulatory Adults With Spinal Muscular Atrophy |
title_short |
Safety, Tolerability, and Effect of Nusinersen in Non-ambulatory Adults With Spinal Muscular Atrophy |
title_full |
Safety, Tolerability, and Effect of Nusinersen in Non-ambulatory Adults With Spinal Muscular Atrophy |
title_fullStr |
Safety, Tolerability, and Effect of Nusinersen in Non-ambulatory Adults With Spinal Muscular Atrophy |
title_full_unstemmed |
Safety, Tolerability, and Effect of Nusinersen in Non-ambulatory Adults With Spinal Muscular Atrophy |
title_sort |
safety, tolerability, and effect of nusinersen in non-ambulatory adults with spinal muscular atrophy |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Neurology |
issn |
1664-2295 |
publishDate |
2021-04-01 |
description |
Objective: Investigation of the safety, tolerability, and treatment effect of nusinersen treatment in non-ambulatory adults with spinal muscular atrophy (SMA).Methods: Non-ambulatory individuals, aged 18 years or older with genetically confirmed 5q SMA were enrolled. In participants with spinal fusion, fluoroscopy guided cervical C1–C2 lateral approach was used. Outcomes at 2, 6, 10, and 14 months post-treatment were compared with baseline assessment. Forced vital capacity (FVC) was the primary outcome, and RULM, HFMSE, the modified SMA-FRS, and ulnar nerve electrophysiology [compound muscle action potential (CMAP), single motor unit size, and motor unit number] were secondary. Adverse and serious adverse events and clinically significant vital sign or lab abnormalities were recorded.Results: Results from 12 women and 7 men (mean age: 39.7 ± 13.9, range: 21–64 years) were analyzed. No clinically significant changes of vital signs or laboratory parameters were observed. Five participants were hospitalized for pneumonia. Other adverse events included headache, back pain, cervical injection site pain, and upper respiratory and urinary tract infections. High baseline protein/creatinine ratio without significant change on treatment noted in 4 participants. FVC was feasible in all participants. HFMSE and RULM were not feasible in the majority of participants. FVC and functional outcomes were stable without improvement. CMAP and single motor unit potential sizes showed enlargement while motor unit numbers were stable.Conclusions: Nusinersen, including C1/C2 delivery, was safe overall and well-tolerated. Several outcome measures were limited by floor effect. Overall, treatment resulted in stability of motor outcomes, but motor unit and CMAP size were increased. |
topic |
adults SMA non-ambulatory nusinersen safety MUNE |
url |
https://www.frontiersin.org/articles/10.3389/fneur.2021.650532/full |
work_keys_str_mv |
AT bakrielsheikh safetytolerabilityandeffectofnusinerseninnonambulatoryadultswithspinalmuscularatrophy AT stevenseveryn safetytolerabilityandeffectofnusinerseninnonambulatoryadultswithspinalmuscularatrophy AT songzhuzhao safetytolerabilityandeffectofnusinerseninnonambulatoryadultswithspinalmuscularatrophy AT davidkline safetytolerabilityandeffectofnusinerseninnonambulatoryadultswithspinalmuscularatrophy AT matthewlinsenmayer safetytolerabilityandeffectofnusinerseninnonambulatoryadultswithspinalmuscularatrophy AT kristinakelly safetytolerabilityandeffectofnusinerseninnonambulatoryadultswithspinalmuscularatrophy AT marcotellez safetytolerabilityandeffectofnusinerseninnonambulatoryadultswithspinalmuscularatrophy AT amybartlett safetytolerabilityandeffectofnusinerseninnonambulatoryadultswithspinalmuscularatrophy AT sarahheintzman safetytolerabilityandeffectofnusinerseninnonambulatoryadultswithspinalmuscularatrophy AT jerryreynolds safetytolerabilityandeffectofnusinerseninnonambulatoryadultswithspinalmuscularatrophy AT garysterling safetytolerabilityandeffectofnusinerseninnonambulatoryadultswithspinalmuscularatrophy AT tristanweaver safetytolerabilityandeffectofnusinerseninnonambulatoryadultswithspinalmuscularatrophy AT kiranrajneesh safetytolerabilityandeffectofnusinerseninnonambulatoryadultswithspinalmuscularatrophy AT stephenjkolb safetytolerabilityandeffectofnusinerseninnonambulatoryadultswithspinalmuscularatrophy AT wdavidarnold safetytolerabilityandeffectofnusinerseninnonambulatoryadultswithspinalmuscularatrophy |
_version_ |
1721525436096184320 |